China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has entered into a local manufacturing memorandum of understanding (MoU) with its Indonesia partner UBC. The agreement will enable Sansure’s molecular diagnostics technology to be manufactured in Indonesia, aimed at enhancing infectious disease prevention and control, as well as diagnosis and treatment capabilities in the Southeast Asian country. Financial details of the partnership were not disclosed.
Subsidiary Establishment and Objectives
Sansure established a subsidiary in Jakarta, Indonesia, last year to provide affordable point-of-care testing (POCT) systems during the COVID-19 pandemic. The company’s scalable POCT diagnostic system is capable of accurately detecting other diseases, including dengue fever and other local infectious diseases. This technology is designed to better meet the scattered disease detection needs of medical institutions in Indonesia and other developing countries, thereby effectively improving local infectious disease prevention and control capabilities, as well as diagnosis and treatment levels.-Fineline Info & Tech
